Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Penumbra, Inc. PEN
$319.68
+$2.3 (0.72%)
На 18:00, 12 мая 2023
-16.32%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
12176969261.00000000
-
week52high
321.43
-
week52low
114.87
-
Revenue
847133000
-
P/E TTM
1827005
-
Beta
0.53979200
-
EPS
-0.06000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 10:59
Описание компании
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Canaccord Genuity | Buy | Buy | 05 авг 2022 г. |
| Deutsche Bank | Buy | Buy | 21 июл 2022 г. |
| RBC Capital | Outperform | 18 июл 2022 г. | |
| BTIG | Buy | Buy | 18 июл 2022 г. |
| Citigroup | Buy | Buy | 17 мая 2022 г. |
| Truist Securities | Buy | Buy | 13 сент 2022 г. |
| Needham | Buy | Hold | 09 сент 2022 г. |
| BTIG | Buy | Buy | 19 сент 2022 г. |
| Citigroup | Neutral | Buy | 05 окт 2022 г. |
| Jefferies | Buy | 12 окт 2022 г. | |
| Wells Fargo | Overweight | Overweight | 04 ноя 2022 г. |
| Needham | Buy | Buy | 04 ноя 2022 г. |
| Citigroup | Buy | Neutral | 04 ноя 2022 г. |
| BTIG | Buy | Buy | 05 дек 2022 г. |
| Truist Securities | Buy | Buy | 20 дек 2022 г. |
| Wells Fargo | Overweight | Overweight | 12 дек 2022 г. |
| Citigroup | Buy | Buy | 12 дек 2022 г. |
| JP Morgan | Overweight | Overweight | 01 февр 2023 г. |
| Piper Sandler | Overweight | 30 янв 2023 г. | |
| BTIG | Buy | Buy | 30 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bose Arani | D | 440662 | 247 | 01 февр 2023 г. |
| Bose Arani | D | 440909 | 889 | 01 февр 2023 г. |
| Bose Arani | D | 441798 | 1224 | 01 февр 2023 г. |
| Bose Arani | D | 443022 | 1540 | 01 февр 2023 г. |
| Bose Arani | D | 444562 | 450 | 01 февр 2023 г. |
| Bose Arani | D | 445012 | 223 | 01 февр 2023 г. |
| Bose Arani | D | 445235 | 427 | 01 февр 2023 г. |
| Kassing Don W. | D | 1545 | 693 | 27 янв 2023 г. |
| Bose Arani | D | 445662 | 20000 | 23 янв 2023 г. |
| Wilder Thomas | D | 214 | 124 | 04 янв 2023 г. |
Новостная лента
Buy These 4 Low-Beta Stocks to Endure Market Volatility
Zacks Investment Research
05 мая 2023 г. в 09:09
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and Novo Nordisk (NVO) are poised to gain.
Penumbra, Inc. (PEN) Q1 2023 Earnings Call Transcript
Seeking Alpha
02 мая 2023 г. в 23:59
Penumbra, Inc. (NYSE:PEN ) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Jee Hamlyn-Harris - Investor Relations Adam Elsesser - Chairman & Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President, Strategy Conference Call Participants Robert Marcus - JPMorgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Imron Zafar - Deutsche Bank Margaret Kaczor - William Blair Michael Sarcone - Jefferies Shagun Singh - RBC Capital Markets Bill Plovanic - Canaccord Genuity Richard Newitter - Truist Securities Mike Matson - Needham & Company Ryan Zimmerman - BTIG Operator Good afternoon. My name is Julianne, and I will be your conference operator today.
Penumbra (PEN) Surpasses Q1 Earnings and Revenue Estimates
Zacks Investment Research
02 мая 2023 г. в 19:09
Penumbra (PEN) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.01 per share a year ago.
Penumbra: Deep Dive Answering Key Investment Questions
Seeking Alpha
07 апр 2023 г. в 06:35
Penumbra has demonstrated its capacity to unlock long-term shareholder value. After a lumpy performance in FY'22, shares have since re-rated more than 100% higher off lows.
Investment in procedural medical devices is safer for valuation, says E Squared's Les Funtleyder
CNBC Television
30 мар 2023 г. в 14:12
Les Funtleyder, portfolio manager for E Squared Capital Management, joins 'The Exchange' to discuss big cap pharma's Q1 performance, the dollar weakness contributing to biotech gains, and investment opportunities in the pharma space.